Kazuhito Ueyama

This inventor holds 3 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignee: Japan Tobacco Inc.. Active years: 2011-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kazuhito Ueyama. Retrieved from https://idiyas.com/inventor/kazuhito-ueyama

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 (Patent Applications = 8)

% Patents Active = 66.7

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 10.8

ph-index = 2

Forward Citations = 8(Granted Patents)

Company Filing History:

3 out of 1,067

Japan Tobacco Inc.

patents

Years Active: 2011-2014

Loading Chart...

3 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8846746 - Pyrazole compound and pharmaceutical use thereof (2014-09-30),

2. 8283465 - Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent (2012-10-09),

3. 8017612 - Piperazine compound and use thereof as a HCV polymerase inhibitor (2011-09-13),

Title: Kazuhito Ueyama: Innovator in Pharmaceutical Compounds

Introduction

Kazuhito Ueyama is a notable inventor based in Takatsuki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative compounds. With a total of 3 patents to his name, Ueyama continues to push the boundaries of medical science.

Latest Patents

Ueyama's latest patents include a pyrazole compound that exhibits SGLT1 inhibitory activity. This invention provides a pharmaceutical composition that can be used for various therapeutic applications. Another significant patent is for a triazolopyridine compound, which acts as a prolyl hydroxylase inhibitor and an erythropoietin production-inducing agent. This compound is particularly useful in treating diseases associated with decreased erythropoietin production.

Career Highlights

Kazuhito Ueyama is currently employed at Japan Tobacco Inc., where he applies his expertise in pharmaceutical research. His work has led to advancements in the development of new therapeutic agents that can address critical health issues.

Collaborations

Ueyama collaborates with esteemed colleagues such as Dai Motoda and Hiroyuki Abe. These partnerships enhance the innovative potential of his research and contribute to the success of his projects.

Conclusion

Kazuhito Ueyama is a prominent figure in the pharmaceutical industry, known for his innovative compounds and significant contributions to medical science. His work continues to impact the field positively, paving the way for future advancements.

Profile summary based on public USPTO records.